RARE SuperRare Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
12:32
Sep 03
Sep 03
Author calls RARE cheap and suggests acquisition interest but does not state a personal.
Author calls RARE cheap and suggests acquisition interest but does not state a personal position or explicit forward call.
LOW
12:11
Sep 03
Sep 03
Premarket movers report mixed price action across major tech and individual stocks driven.
Premarket movers report mixed price action across major tech and individual stocks driven by earnings, guidance, analyst actions, and clinical trial results.
20:15
Sep 02
Sep 02
Short RARE on likely interim miss
Short RARE because setrusumab's sclerostin mechanism won't fix the underlying collagen defect, interim data is very likely to miss, and the pipeline lacks foundational IP.
HIGH
12:26
Aug 20
Aug 20
Premarket movers report mixed results across major stocks.
Premarket movers report mixed results across major stocks, with notable declines in Advance Auto, Alibaba, Coty, and Walmart, while gains were seen in Ethan Allen, Nordson, Ultragenyx, Valvoline, Webull, and a drop in Wolfspeed.
12:56
Aug 17
Aug 17
Reports heaviest selling across specialist funds
"Reports net conviction laggards with heaviest genuine selling across specialist funds in Q2 2026, no directional view."
MED
17:11
Aug 10
Aug 10
The author defends their binary event call accuracy by listing past winners and losers.
The author defends their binary event call accuracy by listing past winners and losers, but frames it as a track record defense rather than a current position or forward call.
LOW
21:52
Mar 02
Mar 02
Jeffrey mentions that for his son's disease (CTD), pharmaceutical companies are looking at "ASO therapy" (Antisense Oligonucleotide) and "prodrugs" to bypass the blood-brain barrier. Ionis (IONS) is the market leader in RNA-targeted ASO therapies, and Ultragenyx (RARE) specializes in rare genetic diseases and metabolic disorders. When a specific modality like ASO is highlighted as the solution for neurological transport issues, it validates the broader technology platforms of these specialized firms. Watch these tickers as proxies for advancements in ASO and rare disease drug delivery. Clinical trial failures are common in rare disease; "science is slow" (as stated by the guest).
About RARE Analyst Coverage
Buzzberg tracks RARE (SuperRare) across 4 sources. 0 bullish vs 1 bearish calls from 4 analysts. Sentiment: mixed to bearish. 7 total trade ideas tracked. Past 7 days: 1 bearish, 2 watch. Latest voices: Martin Shkreli, zerohedge, seedy19tron.